Aerpio Pharmaceuticals, Inc. announced that razuprotafib met the primary efficacy endpoint at Day 28 with the twice-daily (“BID”) dose group in Aerpio’s double-blind, placebo-controlled Phase 2 trial in patients with elevated intraocular pressure (“IOP”) associated with open angle glaucoma (“OAG”) or ocular hypertension (“OHT”). The change from baseline in diurnal mean IOP at Day 28 of study eyes treated with razuprotafib BID plus latanoprost showed a statistically significant improvement, or drop in IOP, (two-sided p-value 0.0130 and LS mean difference of -0.92 mm Hg) compared to those treated with latanoprost monotherapy.  The razuprotafib once-daily (“QD”) dose group did not show a statistically significant improvement at Day 28. The study was designed to evaluate the safety and efficacy of a topical ocular formulation of razuprotafib as an adjunct to standard of care latanoprost. A total of 194 patients completed a 28-day washout period and were randomized in a 1:1:1 fashion to receive latanoprost ophthalmic solution 0.005% once daily with adjunctive therapy consisting of placebo, 40 mg/ml razuprotafib once-daily, or 40 mg/ml razuprotafib twice-daily. The primary endpoint of the study was mean diurnal IOP at 28 days in the razuprotafib treated groups compared to the latanoprost monotherapy group.